How does Emend (aprepitant) work for chemotherapy-induced nausea?
Emend (aprepitant) is an antiemetic used as part of a regimen to prevent chemotherapy-induced nausea and vomiting (CINV). It blocks NK1 (neurokinin-1) receptors, which helps reduce nausea and vomiting triggered by chemotherapy.[1]
Is Emend effective for CINV?
Yes. Emend is effective for chemotherapy-induced nausea, especially when used with other standard antiemetics (commonly a 5-HT3 antagonist and a corticosteroid) in patients receiving chemotherapy.[1]
Which types of chemotherapy nausea does Emend target?
Emend is used to reduce both the early phase and delayed phase of CINV, which are different time windows after chemotherapy dosing. Its role in delayed nausea is a key reason it is included in multi-drug antiemetic regimens.[1]
What results should patients expect?
Patients are typically prescribed a combination antiemetic plan to lower the overall risk of nausea and vomiting after chemotherapy. Clinical use focuses on preventing symptoms rather than treating them after they start, with Emend added to improve control—particularly for delayed nausea.[1]
What if someone already takes other anti-nausea medicines?
Emend is generally not used alone. It is intended to be added to the broader CINV prevention regimen because combining drugs with different mechanisms improves nausea and vomiting control across different phases after chemotherapy.[1]
Sources
[1] https://www.drugpatentwatch.com/patent/Emend.html